Applies to a specific decision
This is a decision-scoped read for a person considering a GLP-1 for weight. The answer turns on baseline cardiometabolic risk — the same drug is a proven hard-outcome lever for one person and a surrogate-only weight change for another. It is not population-wide advice to start or avoid it.
The drug is two decisions wearing one name
A GLP-1 receptor agonist does the same thing to everyone’s appetite — it resupplies a satiety signal from the outside, so you eat less. But its value forks on who takes it, because the benefit that matters most — a prevented heart attack, stroke, kidney failure, or death — scales with the risk a person already carries. Sort by baseline cardiometabolic risk and the drug resolves into two answers wearing one name.
For a person with obesity and established cardiovascular disease, kidney disease, or type-2 diabetes, this is a large, proven lever on the outcomes that count — a Big Rock, not a refinement. Semaglutide reliably cuts hard cardiovascular events and death in secondary prevention, and a class-level meta-analysis now shows that benefit is a property of the whole drug class, not one molecule. In diabetic kidney disease it slows hard kidney outcomes too.
For a near-normal-weight person with no cardiometabolic disease, the picture inverts. The weight loss is large and reliable, but it is a surrogate: any reduction in heart attacks, strokes, kidney failure, or death is unproven, because the hard-outcome trials enrolled only high-risk patients. This person pays the same tolerability cost — and, in serious-event terms, nets more harm than benefit, because few hard events stand to be averted. The weighing between a certain surrogate gain and an unproven hard-outcome one is irreducibly theirs.
Every section below rests on two facts. The benefit is a maintained state, not a cure — it lasts only while the drug is taken. And the class is not uniform: tirzepatide takes off more weight than semaglutide but has no hard-outcome trial at all, so a bigger number on the scale does not carry a bigger proven benefit.
What the drug reliably does is make you eat less
The best-evidenced effect is on body weight, and its size depends on the agent and the population. In STEP-1 — semaglutide 2.4 mg weekly in non-diabetic obese adults (mean age 46), adjunct to lifestyle — mean weight fell 14.9% versus 2.4% on placebo at week 68, a placebo-adjusted 12.4 percentage points (95% CI 11.5 to 13.4) (Wilding et al., 2021). In SELECT — the same drug in an older secondary-prevention population — the effect was smaller, roughly 9-10%, a difference of 8.5 points at week 104 (Lincoff et al., 2023).
The response is heterogeneous — a mean of ~15% hides both big responders and non-responders. STEP-1 makes the spread explicit: 69% of the semaglutide arm lost ≥10%, 51% lost ≥15%, and 32% lost ≥20% (versus 12%, 5% and 2% on placebo) — so a substantial minority did not reach even 10% (Wilding et al., 2021). The mean is not the individual estimate.
Tirzepatide is a distinct drug, not a stronger dose of the same one. It is a dual GIP/GLP-1 receptor agonist — it adds a second receptor axis rather than intensifying GLP-1 agonism. In SURMOUNT-1 (the same non-diabetic obese class as STEP-1), weight fell 15.0%, 19.5%, 20.9% at 5/10/15 mg versus 3.1% placebo, with half to 57% of the top two doses losing ≥20% (Jastreboff et al., 2022).
A network meta-analysis of 262 trials (99,791 participants, 19 drugs) ranks the class against a common reference — lifestyle alone — supplying the head-to-head the single-drug trials cannot. At one year tirzepatide takes off 14.9% (95% CI 13.9 to 16.0) against subcutaneous semaglutide’s 9.8% (9.1 to 10.6), both at moderate-to-high certainty (Nong et al., 2026) -> Comparing Obesity Drugs. The pivotal trials cannot be compared directly: «no direct comparison of these trials can be made, since trial populations and designs differed» (Jastreboff et al., 2022).
Every one of these numbers is a surrogate. Weight is a marker; whether moving it moves an outcome a person actually cares about is a separate evidenced step, never assumed from the scale -> Surrogate Outcomes. That discipline bites hardest exactly here, where the effect is so large and reliable that reading the surrogate as the outcome is most tempting.
Hard cardiovascular events fall as a class — but the benefit is proven where risk is high
This is the outcome that turns the drug from a weight intervention into a lever on something people care about, and the evidence has grown from one trial to a class.
SELECT is the landmark for the obese, non-diabetic stratum. In 17,604 patients aged 45+ with established cardiovascular disease and a BMI ≥27, on top of standard care (90% on statins, 86% on antiplatelets), semaglutide 2.4 mg cut the primary MACE composite (CV death, non-fatal MI, non-fatal stroke) from 8.0% to 6.5% over a mean 39.8 months — HR 0.80 (95% CI 0.72-0.90) (Lincoff et al., 2023). That is a 1.5-percentage-point absolute reduction, an NNT of about 67 over ~3.3 years (inferred from Lincoff et al., 2023) — incremental benefit on top of guideline therapy, not instead of it.
The class-level meta-analysis now shows this is not a semaglutide one-off. Badve 2024 pools 11 cardiovascular-outcome trials (85,373 participants, median follow-up ~2 years) and finds the whole GLP-1 receptor agonist class cuts MACE — HR 0.87 (0.81-0.93) in type-2 diabetes, 0.86 (0.80-0.92) with SELECT added, NNT 74 — and all-cause death HR 0.88 (0.83-0.93), NNT 101, both high-certainty and consistent regardless of diabetes status (Badve et al., 2025).
Badve calls the class «the first and only class of medications with proven benefits on composite kidney and cardiovascular outcomes… across a range of cardiovascular risk and chronic kidney disease severity in people with and without diabetes» (Badve et al., 2025). This is what the single-agent trials could not establish: the CV/mortality benefit is a class property, robust to leaving out any one trial -> GLP-1 Receptor Agonists and Cardiovascular and Kidney Outcomes.
But Badve is not a second independent line — it pools SELECT and shares its authors — so it is refinement of the same evidence, not corroboration by a separate route. And crucially, the class benefit is largely weight-independent: these are glucose-lowering trials with modest weight loss, and the CV benefit separates early, before much weight is lost. So this evidence reinforces — does not overturn — the finding that losing weight by itself is not a guaranteed cardiovascular lever -> Does Weight Loss Reduce Cardiovascular Events.
The composite is carried by non-fatal events, not deaths
Only SELECT’s primary composite is a confirmatory result. Its pre-specified gatekeeping hierarchy tested CV death next, and that test failed — HR 0.85 (0.71-1.01), P=0.07 — so superiority testing stopped there and everything downstream is a point estimate, not a confirmed effect (Lincoff et al., 2023):
| Endpoint | HR (95% CI) | Confirmatory status |
|---|---|---|
| Primary MACE | 0.80 (0.72-0.90), P<0.001 | Confirmatory — hit |
| CV death | 0.85 (0.71-1.01), P=0.07 | Failed the pre-specified gate |
| All-cause mortality | 0.81 (0.71-0.93) | Exploratory (below the failed gate) |
| Heart-failure composite | 0.82 (0.71-0.96) | Exploratory |
| Non-fatal MI | 0.72 (0.61-0.85) | Favourable, exploratory |
| Non-fatal stroke | 0.93 (0.74-1.15) | Not reduced |
Read this without either error. The CV-death miss is not evidence of no effect — its interval still spans a meaningful benefit, and the endpoint was gatekept and underpowered. It means the trial did not license a confirmatory claim there, so P=0.07 must not be read as significance. All-cause mortality (0.81) is directionally favourable and, at the class level, high-certainty in Badve. Non-fatal MI carries most of the composite, while stroke was not reduced and CV death did not clear the gate. So within SELECT, MACE fell but CV deaths did not — MACE was reduced must not be read as deaths were reduced (inferred from Lincoff et al., 2023).
For a low-risk person the benefit is unproven, not merely unstated
SELECT’s trialists draw the boundary in their own words: «we included only patients with preexisting cardiovascular disease. The effects of semaglutide on primary prevention of cardiovascular events in persons with overweight or obesity but without previous atherosclerotic disease were not studied.» (Lincoff et al., 2023). Badve’s class effect is robust, but SELECT is still the only non-diabetic trial in the pool, so the primary-prevention gap is intact.
The gap does not close by transporting the relative effect. Absolute benefit is the relative reduction applied to a person’s own baseline risk, so a constant hazard ratio buys a shrinking return as risk falls Baseline Risk and the Relative-Absolute Split. A primary-prevention person at ~5% ten-year risk sits roughly five-fold below SELECT’s event rate; apply the same HR 0.80 and the ~1.5-point reduction shrinks toward a fraction of a percentage point. The hard-CV benefit for a low-risk, near-normal-BMI person is expected-small and never tested — insufficient evidence, not a demonstrated null (inferred from Lincoff et al., 2023).
Tirzepatide has no hard-CV trial at all
The class’s strongest weight lever is the one with the least outcome evidence. Tirzepatide’s pivotal obesity trial measured weight, a surrogate, and its cardiovascular morbidity-mortality trial does not yet exist:. Across the 19-drug network, subcutaneous semaglutide is the only agent reaching a mortality (RR 0.81) or MI (0.72) signal — and the network flags that limb as «largely informed by cardiovascular outcome trials in high risk populations», i.e. SELECT re-pooled, not new corroboration (Nong et al., 2026). Tirzepatide reaches a heart-failure signal in the same network (HR 0.49, 0.27-0.88) but no mortality or MI benefit (Nong et al., 2026), and a network estimate is not a dedicated outcome trial.
A record-breaking weight number does not license a hard-outcome claim: Look AHEAD is the standing worked case where a large surrogate improvement bought no measurable event reduction -> Does Weight Loss Reduce Cardiovascular Events. Until SURMOUNT-MMO reports, tirzepatide’s hard-CV effect is insufficient-evidence, not no-effect.
The kidney is now its own proven leg
Kidney disease is a third distinct benefit, on a different endpoint in a different stratum — and the evidence now runs from one dedicated trial up to the class.
FLOW is the first dedicated hard-outcome kidney trial of a GLP-1 drug. It enrolled a narrow, high-risk population: type-2 diabetes with established chronic kidney disease (eGFR 25-75, elevated albuminuria), already on a maximal-dose RAS inhibitor, mean eGFR 47, BMI 32, age 66.6; semaglutide 1.0 mg weekly (the glycaemic dose, not the 2.4 mg obesity dose), n=3533, median 3.4 years, stopped early for efficacy (Perkovic et al., 2024). On that stratum the effect is large and patient-important:
- Major kidney disease events (primary composite): HR 0.76 (95% CI 0.66-0.88), P=0.0003, 5.8 vs 7.5 events/100 patient-years, NNT 20 over 3 years (14-40).
- Death from any cause: HR 0.80 (0.67-0.95), NNT 39; death from CV causes HR 0.71 (0.56-0.89); MACE HR 0.82 (0.68-0.98), NNT 45 — the survival signal, not just the renal one (Perkovic et al., 2024).
Two qualifiers keep it honest. The composite is not all hard kidney failure — it pools kidney failure (dialysis/transplant) with a surrogate ≥50% eGFR-decline threshold and death, and FLOW was not powered for kidney failure alone. The defensible claim is reduced a composite of kidney events and reduced death, not prevented dialysis on its own. And the benefit was weight-independent — creatinine- and cystatin-C-based eGFR agreed, so it is not merely weight loss lowering serum creatinine (Perkovic et al., 2024).
Badve raises the kidney finding to a class effect on a hard outcome. The prior class analysis credited a kidney benefit «mainly driven by new-onset macroalbuminuria, a surrogate outcome not validated for clinical kidney disease outcomes»; Badve re-runs it on a composite that excludes macroalbuminuria — HR 0.82 (0.73-0.93), high-certainty, NNT 164 — and, for the first time, demonstrates a class-level kidney-failure reduction, HR 0.84 (0.72-0.99), moderate-certainty (Badve et al., 2025). Kidney failure is not creatinine-confoundable, which anchors the composite against the muscle-loss artifact: «The separately significant reduction in the risk of kidney failure provides important reassurance that the kidney benefits of GLP-1 receptor agonists are real and clinically important» (Badve et al., 2025). FLOW carried 49% of that kidney-failure weight, so this is largely FLOW confirmed at scale, not an independent route.
The absolute kidney benefit is modest outside high kidney risk. Badve’s pooled trials mostly enrolled near-normal kidney function (mean baseline eGFR 77), so the class kidney NNT runs to 164 (Badve et al., 2025) against FLOW’s 20 (Perkovic et al., 2024). The relative effect is real, but the payoff scales with baseline kidney risk (route (a)) and is decision-moving mainly in the FLOW-type stratum. It does not transport to a low-risk, near-normal-BMI person -> Semaglutide and Kidney Outcomes in Chronic Kidney Disease.
Progression to diabetes drops sharply
Two-thirds of SELECT was prediabetic, and progression to diabetes fell steeply — progression to HbA1c ≥6.5% ran at HR 0.27 (95% CI 0.24-0.31) (Lincoff et al., 2023). STEP-1 shows the same in a younger population: 84% of prediabetic participants on semaglutide reverted to normoglycaemia by week 68 versus 48% on placebo (Wilding et al., 2021). For an obese, impaired-fasting-glucose person this is a distinct, plausibly-relevant benefit — but it sits on a glycaemic-threshold surrogate plus a progression endpoint, not on a hard diabetes-complication outcome. Whether it lowers those hard outcomes in primary prevention inherits the same insufficient-evidence caveat as the CV case.
Fatty liver improves on the same weight lever
Weight loss of the magnitude these drugs produce improves fatty-liver (MASLD) disease in a dose-dependent way; the full steatosis/inflammation/fibrosis threshold ladder lives on Body Fat.
Muscle comes off with the fat — the ratio improves while absolute mass falls
The dedicated synthesis is a meta-analysis of 7 RCTs at obesity doses (821 patients), and its finding has two faces that must be read together (Laverde et al., 2026). As a proportion of total weight, lean mass rises — +1.81% (95% CI 1.1 to 2.52; I²=7%) — because fat is shed faster than lean, so body composition improves as a ratio. In absolute terms, muscle is lost — −1.74 kg (−3.04 to −0.45; I²=98%), a −3.06% fall. Semaglutide is the outlier on both counts: −5.44 kg, −9.9%. The near-98% heterogeneity is itself a reason to hold the absolute figure loosely.
Laverde’s own verdict lands on the ratio face — «lean mass loss should not be considered a limitation for the use of these drugs in patients with obesity» (Laverde et al., 2026) — which is faithful to the composition data and not a denial that absolute muscle falls; both are true at once.
The lost muscle is roughly what any rapid loss costs — not a drug-specific hazard. Of total mass lost, about 30% is lean, «comparable to that observed after bariatric surgery» and at or just inside the ordinary 20-30% diet-induced band. Per agent: liraglutide 14-22%, tirzepatide ~26%, semaglutide up to 45% — above the band, the one agent that earns a specific worry (Laverde et al., 2026). The class network agrees on rank: the biggest fat-loss drugs (tirzepatide −8.3%, subcutaneous semaglutide −5.8%, both moderate certainty) are the worst for lean mass (Nong et al., 2026) -> GLP-1 and Lean Mass. So on the class average the lean loss is generic to rapid weight loss, with semaglutide the exception. The wiki holds no head-to-head against a matched, same-magnitude non-drug loss, so the attribution is directional, not settled.
Function is unmeasured — the streetlight gap. Composition is measured; the outcome people actually care about is not. «The included studies did not evaluate functional outcomes, such as muscle strength or physical capacity» (Laverde et al., 2026). Lean mass is a surrogate for muscle mass, which is a surrogate for strength, gait speed, falls, and independence. A reassuring ratio does not prove function is spared, and a scary kilogram figure does not prove it is lost — hold this as insufficient evidence on function, not as safe or harmful -> Sarcopenia Definition and Diagnosis.
Which face governs is a matter of stratum, and it inverts. Laverde ran in «relatively young populations with a low burden of comorbidities» — the wrong population for the worry (Laverde et al., 2026):
- Young, high-BMI adult with abundant muscle: the ratio face governs — composition improves, the absolute loss is minor and recoverable. Rank the muscle cost low.
- Older / sarcopenia-risk / multimorbid adult: the absolute face governs — the same kilograms become a front-line harm (falls, fractures, lost independence). And the drug’s own appetite suppression fights the defense, because sparing muscle needs more protein exactly when intake is cut. Resistance training and adequate protein lower the functional cost without touching the weight benefit, but monitor on function, not on weight (inferred from Laverde et al., 2026) -> Big Rocks (Elderly), Protein and Resistance Training for Muscle and Strength.
The safety ledger: worry about the gut, not the cancers
Read each entry on two axes at once, because the umbrella evidence grades them on two that routinely disagree — GRADE certainty (how well the effect is estimated) and credibility class (how robust the association is to bias) (Yang et al., 2026). Within the gastrointestinal cluster, nausea is GRADE-high but credibility-weak, while vomiting is GRADE-moderate but highly suggestive — so a headline quoting one number misleads -> Rating Certainty of Evidence.
Gastrointestinal effects are the one robust harm. Nausea OR 2.47 (1.84-3.34), vomiting 2.78 (1.91-4.06), diarrhoea 1.94 (1.52-2.49) — established, not exploratory (Yang et al., 2026). Two facts decide how much they weigh: the tax is largely dose- and titration-dependent (it tracks how fast the dose is escalated) and mostly transient and early (it fades with continued use). It is the dominant real-world adherence cost — reflected in a class-level discontinuation-for-adverse-events rate of RR 1.51 (1.18-1.94) (Badve et al., 2025) — and it is already priced into the drug decision.
The serious-adverse-event balance inverts by stratum. In FLOW’s high-risk diabetic-CKD population serious events were fewer on semaglutide (49.6% vs 53.8%) (Perkovic et al., 2024); in STEP-1’s lower-risk obese population they ran higher (9.8% vs 6.4%), the excess driven by serious gastrointestinal (1.4% vs 0%) and hepatobiliary (1.3% vs 0.2%) events (Wilding et al., 2021). Where many hard events stand to be prevented, the drug averts serious events on net; where few do, it adds them — the mirror image of the high-risk benefit, and a cost the weight number hides.
The most-feared cancers show no robust human signal — but that is not exoneration. Thyroid cancer, the rodent C-cell scare, came back imprecise and non-significant (OR 1.43, 0.95-2.13, P=.08), and pancreatic cancer’s nominal signal ran the other way, toward lower odds (OR 0.51, 0.30-0.85) (Yang et al., 2026). The trials run months to a few years; a long-latency malignancy could not realistically have surfaced yet (the expectancy test with a latency caveat), so absence of a short-term signal is not a long-term all-clear.
Between the robust harm and the absent one sits an unsettled middle — each demoted for a different reason. Gallbladder or biliary disease is a statistically significant association (OR 1.34, 1.16-1.55, P<.001), demoted only because its prediction interval sits near the null — a robustness caveat, not a doubt about the harm; gastro-oesophageal reflux holds the same posture (OR 2.19, 1.65-2.90). Pancreatitis is different in kind: here the demotion is about causality — the consensus on whether GLP-1 drugs cause it is explicitly unsettled, with a propensity-matched analysis finding no excess against a regulatory update flagging rare fatal cases (Yang et al., 2026). Lumping the three is the error.
Some off-target signals point the protective way — candidates to watch, not banked benefits. Fewer serious infections (OR 0.89, 0.87-0.92, the one convincing class-I signal), fewer fractures (0.67, 0.52-0.87), and less all-cause dementia (0.55, 0.35-0.87) (Yang et al., 2026). The reduced-fracture signal offsets the sarcopenia/fall worry above; the dementia signal, if real, is decision-relevant.
But a second umbrella shows the dementia effect is not GLP-1-specific. Across antidiabetic classes, GLP-1 drugs were associated with lower dementia risk (RR 0.35, 0.16-0.78) — but so were metformin, the thiazolidinediones, and SGLT2 inhibitors, while sulphonylureas ran the other way, and the estimate carries near-total heterogeneity (I²=98.5%) (Kuate Defo et al., 2023). A protective signal shared across unrelated glucose-lowering classes points at glycaemic control or confounding by indication rather than anything GLP-1-specific; both umbrellas pool the same observational pharmacoepidemiology, so they cannot cross-confirm. The dementia entry stays a watched protective blank.
Two facts make any version of this ledger provisional. First, mechanical fragility: in leave-one-trial-out reanalysis, the direction flipped in roughly 9 of 39 outcomes and significance was lost in 6 of 39 after removing a single trial. An association a single trial can overturn is not one to dose a recommendation on (Yang et al., 2026). Second, a moving target. The mature multi-year evidence sits on one older molecule (semaglutide), while prescribing moves to agents that add receptor targets it never tested (tirzepatide adds GIP) and to higher doses. And the umbrella could not stratify harms by dose or duration. Accrued safety years de-risk the specific compound at the specific dose that accrued them; the class label stays constant while the exposure under it drifts -> GLP-1 Non-Cardiometabolic Effects and Safety.
Stopping the drug gives the weight back — and the benefit with it
The effect lasts only while the drug does. When semaglutide and its lifestyle programme were both withdrawn at week 68, participants regained a mean 11.6 percentage points of body weight over the following year (versus 1.9 on placebo). That is about two-thirds of the loss, leaving a net ~5.6% below baseline, and their cardiometabolic gains drifted back toward baseline (Wilding et al., 2022). The class-wide rate is similar: roughly 0.4 kg regained per month, a projected return to baseline within ~1.7 years, with about half of patients discontinuing within the first year (Nong et al., 2026).
This is defended physiology, not weak resolve. After weight loss the body’s satiety signals stay suppressed (leptin ~35% below baseline) and hunger stays elevated, and those shifts persist a full year out — so the relapse «has a strong physiological basis and is not simply the result of the voluntary resumption of old habits» (Sumithran et al., 2011). A GLP-1 drug does not cure this; it resupplies one of the depleted satiety signals from outside, overriding the defended set point only while present. Remove it and the deficit reasserts -> Weight-Loss Maintenance and Metabolic Adaptation. One caveat: the STEP-1 extension withdrew the lifestyle support too, so it cannot cleanly separate biological rebound from behavioural drift.
So the real decision is a lifetime one, across three routes to a sustained result. Unaided behavioural maintenance works against the defended physiology, so regain is the modal outcome. Indefinite drug therapy holds the weight and the benefit only for as long as it is taken and paid for. Bariatric surgery is the durable-structural comparator: in SOS, sustained loss of 14-25% at 10 years came with an all-cause mortality reduction — adjusted HR 0.71 (P=0.01) — that does not depend on daily adherence (Sjöström et al., 2007). SOS is non-randomized and carries its own peri-operative harm, so it is not a clean head-to-head. But it anchors the one thing the drug route structurally lacks — a benefit that survives the intervention being over -> Does Weight Loss Reduce Cardiovascular Events.
Name the second axis and stop. Indefinite therapy loads heavily on an axis the health evidence cannot price: drug cost, access, supply, and the demand for lifelong adherence. The discipline is to record that this trade-off exists and which way it runs — the continuation-dependent route is the most exposed — and to stop there, not to net it against the mortality and event findings. Whether lifelong cost outweighs a rented benefit is the person’s judgment, not a number this evidence supplies -> Which Objective Moved This Recommendation.
What the current evidence still cannot see
These are gaps — insufficient evidence, not no effect -> The Insufficient-Evidence Statement. That distinction does real work here: the trials run a few years while people take the drug for decades, and this horizon mismatch is structural — more searching now cannot close it.
- Lifetime and long-latency outcomes are unmeasured. Cancer over a full latency window, bone and fracture over decades, pregnancy and fetal exposure, adolescent development, and cardiometabolic status after discontinuation all sit in the insufficient-evidence state. For a long-latency harm, absence of a signal in a few-year trial base is exactly what you would see whether or not the harm is real — so the current quiet licenses neither alarm nor an all-clear.
- Attribution — drug-specific versus generic to the loss — is unresolved. Lean-mass loss and facial/skin adipose change may be effects of rapid, large weight loss by any route rather than of the molecule. Separating them needs a matched comparator losing the same magnitude at the same rate by other means, and none is held.
- Unknown unknowns are unquantifiable — so name the two honest proxies. No list exists of harms nobody has measured. What can be stated is the shape that makes them likely and hard to catch: the evidence-horizon-versus-use-horizon mismatch above, and the moving-target problem — the exposure drifts under a constant label as prescribing moves to newer molecules and higher doses the mature record never tested. Accrued years de-risk the specific compound and dose, not the class label.
Where you net out
Start from your baseline risk, not the scale. If you have established cardiovascular disease, or type-2 diabetes with kidney disease, a GLP-1 is a large, proven lever on the outcomes that matter — cardiovascular events, death, and hard kidney outcomes — and it ranks as a Big Rock. If you are near-normal weight with no cardiometabolic disease, you are buying a reliable weight and surrogate change whose hard-outcome payoff is unproven, at the same adverse-event cost — and net serious harm runs slightly against you. Place yourself in the right stratum before deciding anything else.
Expect a maintained state, not a course. Stopping returns about two-thirds of the lost weight within a year, because the body defends the higher weight. Budget cost, tolerability, and reversibility over years, and compare that against a sustained lifestyle change or surgery on the same terms — not against an idealized one-time fix.
If you proceed, protect muscle — resistance training and adequate protein lower the functional cost without touching the weight benefit, most urgently in older or frailty-risk adults -> GLP-1 and Lean Mass.
Then weigh the trade-off yourself. The evidence names what the drug moves, in which direction, and how certainly — weight and diabetes-progression reliably; hard cardiovascular, kidney, and mortality outcomes where baseline risk is high; a manageable gut cost; feared cancers with no robust signal but no long-term all-clear. It does not price weight change against gastrointestinal burden, lifelong cost, or an event benefit proven for one stratum and unproven for another. Bring your own weighting; the fabric supplies only the directions and the certainties.
Evidence box
Question ’For a person considering a GLP-1 / GIP-GLP-1 receptor agonist (semaglutide, liraglutide, tirzepatide) primarily for weight: what is the effect on each patient-important outcome — weight and appetite, glycaemia, cardiovascular events, kidney, adverse effects, lean-mass loss, discontinuation and regain — for whom, how large, how certain, and how does that answer change by stratum?‘ Evidence included 12 sources — 4 gold, 8 high Overall certainty Medium (see Rating Certainty of Evidence) Source-selection note All sources are gold or high tier. Last updated 2026-09-05 · Independently reviewed: No · Full edit history